New data demonstrates extensive activity of Shionogi’s antibiotic cefiderocol
pharmafile | July 12, 2021 | News story | Sales and Marketing |
Shionogi’s novel antibiotic, cefiderocol, has extensive in vitro activity against some of the most difficult to treat carbapenem-resistant Gram-negative bacteria.
The susceptibility profiles of cefiderocol and comparators were evaluated against a European and US collection of Gram-negative bacteria as part of the SENTRY Antimicrobial Surveillance Program.
In these studies, the in vitro activity of cefiderocol was evaluated against non-fermenters such as P. aeruginosa, A. baumannii-calcoaceticus complex, and S. maltophilia, as well as Enterobacterales isolates, including carbapenem-resistant strains.
Cefiderocol also demonstrated broad activity against the isolates resistant to recently approved beta-lactam / beta-lactamase inhibitor combinations. For the resistant phenotypes, cefiderocol was the most active agent tested.
Dr Dee Shortridge, Senior Director for Antimicrobial Development at JMI Laboratories, said: “These data from the SENTRY studies are very encouraging as they show that cefiderocol is broadly active against Enterobacterales and non-fermenters like Pseudomonas, Acinetobacter and Stenotrophomonas, including multidrug resistant strains, performing better than all other comparators tested.
“Infections caused by multidrug resistant Pseudomonas are inherently difficult to treat as many antibiotics are not effective against this critical pathogen.
“Increasing resistance in Gram-negative bacteria is a real issue, especially where it compromises carbapenems.”
Additionally, encouraging real-world data are emerging, both from use on compassionate grounds and also from the Early Access Programme, in which over a third of patients receiving cefiderocol for a Gram-negative bacterial infection were co-infected with COVID-19.
The most common infections were pneumonia and BSI/sepsis, of the 237 patients treated with cefiderocol, 37.1% were also co-infected with COVID-19.
Studies have shown the prevalence of carbapenem-resistant Gram-negative isolates which are associated with high mortality and unmet need.
Initial data shows that cefiderocol is addressing this unmet need for new antimicrobials effective against important resistant pathogens, such as carbapenem-resistant Acinetobacter or Pseudomonas – two of the pathogens listed as “critical priority” by the WHO.
Dr Mark Hill, Global Head of Market Access, Shionogi, said: “Shionogi is excited to share these real-world data at ECCMID, providing initial evidence that cefiderocol is addressing the high unmet need for new antimicrobials effective against important resistant pathogens, such as carbapenem-resistant Acinetobacter or Pseudomonas.
“Antimicrobial resistance is a major health burden responsible for approximately 700,000 deaths globally every year, and it is of critical importance that we continue to develop effective new treatments to tackle this growing threat.”
Lilly Subbotin
